All In Biotech

Drug Trial Radar · NCT00045032

Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer

A Randomized Three-Arm, Multicenter Comparison of 1 Year and 2 Years of Herceptin Versus No Herceptin in Women With HER2-Positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy

Last checked: Nov 20, 2026Latest source record: Apr 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 5,099 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

5,099

Actual

Start

Nov 2001

Primary completion

Mar 2005

Study completion Jun 2015

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Breast International Group; European Organisation for Research and Treatment of Cancer - EORTC; NCIC Clinical Trials Group; ETOP IBCSG Partners Foundation
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to evaluate Herceptin treatment for 1 year and 2 years (versus observation/no Herceptin) in women with HER2-overexpressing primary breast cancer who have completed (neo-)adjuvant systemic chemotherapy, definitive surgery, and radiotherapy, if applicable. Efficacy and safety will be assessed for 10 years from randomization for each participant. All participants will continue to be followed for survival until 10 years after enrollment of the last participant.

Conditions

  • Breast Cancer

Interventions

  • HerceptinDrug

    Herceptin will be given as a loading dose of 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.

  • HerceptinDrug

    Herceptin will be given as a loading dose of 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Disease-Free Survival (DFS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-UpTime frame: From Baseline until time of event (median of 1 year)
  2. Percentage of Participants With DFS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-UpTime frame: From Baseline until time of event (median of 1 year)
  3. DFS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-UpTime frame: Year 2
  4. DFS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-UpTime frame: Year 2
  5. Percentage of Participants With DFS Events Compared to Observation: 8-Year Median Follow-UpTime frame: From Baseline until time of event (median of 8 years)
  6. DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-UpTime frame: Year 3
  7. DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-UpTime frame: Year 5
  8. DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-UpTime frame: Year 7
  9. DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-UpTime frame: Year 8
  10. Percentage of Participants With DFS Events Compared to Observation: 10-Year Maximum Follow-UpTime frame: From Baseline until time of event (maximum of 10 years)
  11. DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-UpTime frame: Year 3
  12. DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-UpTime frame: Year 5
  13. DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-UpTime frame: Year 7
  14. DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-UpTime frame: Year 8
  15. DFS Rate at Year 9 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-UpTime frame: Year 9
  16. DFS Rate at Year 10 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-UpTime frame: Year 10

Locations

203 sites in 33 countries. Site status is shown where the registry gives one.

  • Hospital Aleman de Buenos Aires

    Buenos Aires, Buenos Aires, Argentina

  • Saint John of God Hospital

    Geelong, Australian Capital Territory, Australia

  • Toowoomba Hospital

    Toowoomba, Queensland, Australia

  • Andrew Love Cancer Centre

    Geelong, Victoria, Australia

  • Mount Hospital

    Perth, Western Australia, Australia

  • Landeskrankenhaus Feldkirch

    Feldkirch-Tisis, Austria

  • Innsbruck Universitaetsklinik

    Innsbruck, Austria

  • Landeskrankenhaus Klagenfurt

    Klagenfurt, Austria

  • St. Vincent's Hospital

    Linz Donau, Austria

  • Landeskrankenanstalten - Salzburg

    Salzburg, Austria

  • Landeskrankenhaus St. Poelten

    Sankt Pölten, Austria

  • Universitaetsklinik fuer Innere Medizin I

    Vienna, Austria

  • Wilhelminenspital der Stadt Wien

    Vienna, Austria

  • LKH Villach

    Villach, Austria

  • LKH Voecklabruck

    Vöcklabruck, Austria

  • A. oe. Krankenhaus Wiener Neustadt

    Wiener Neustadt, Austria

  • Ziekenhuis Netwerk Antwerpen Middelheim

    Antwerp, Belgium

  • Reseau Hospitalier De Medecine Sociale

    Baudour, Belgium

  • Hopital Universitaire Erasme

    Brussels, Belgium

  • Academisch Ziekenhuis der Vrije Universiteit Brussel

    Brussels, Belgium

  • Institut Jules Bordet

    Brussels, Belgium

  • Centre Hospitalier Notre Dame - Reine Fabiola

    Charleroi, Belgium

  • Cazk Groeninghe - Campus St-Niklaas

    Kortrijk, Belgium

  • Centre Hospitalier Universitaire de Tivoli

    La Louvière, Belgium

  • U.Z. Gasthuisberg

    Leuven, Belgium

  • Clinique Saint-Joseph

    Liège, Belgium

  • CHU Liege - Domaine Universitaire du Sart Tilman

    Liège, Belgium

  • Clinique Sainte Elisabeth

    Namur, Belgium

  • Hospital Serruys Ziekenhuis

    Ostend, Belgium

  • Centre Hospitalier Peltzer-La Tourelle

    Verviers, Belgium

  • Hospital Sao Lucas da PUCRS

    Porto Alegre, Brazil

  • Hospital Santa Rita

    Porto Alegre, Brazil

  • Instituto Nacional de Cancer

    Rio de Janeiro, Brazil

  • Faculdade De Medicina Do ABC

    Santo André, Brazil

  • Porto Alegre Hospital

    Porto Alegre, Rio Grande do Sul, Brazil

  • Tom Baker Cancer Centre - Calgary

    Calgary, Alberta, Canada

  • British Columbia Cancer Agency - Centre for the Southern Interior

    Kelowna, British Columbia, Canada

  • Fraser Valley Cancer Centre at British Columbia Cancer Agency

    Surrey, British Columbia, Canada

  • British Columbia Cancer Agency - Vancouver Cancer Centre

    Vancouver, British Columbia, Canada

  • British Columbia Cancer Agency - Vancouver Island Cancer Centre

    Victoria, British Columbia, Canada

Showing 40 of 203 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.